Ankar Pharma worked to develop new therapies to improve the quality of life of the patients
Ankar Pharma is a spin-off from the Scientific Investigation Superior Council (CSIC in Spanish), which mission is to develop new therapies that find a cure or improve the quality of life of multiple sclerosis patients. It joined the GAEM Accelerator in 2014.
The main achievement by Ankar Pharma is the AP-01 molecule, the firs of its class that is able to regain mielyn and protects the neurons. After showcasing in animal models the efficacy of the main components of the molecule (including neuro-protection, reducing symptoms, gain mielyn and reduce the progress of the disease), in 2017 they started pre-clincal trials to show the safety of the project.
The start of the clinical fase I was scheduled to start in 2019.